Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PDS BiotechnologyFRA:EU6 -3.36%30 EV-to-OCF is -0.61 as of Sep. 02, 2026. GuruFocus rates FRA:EU6 with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,407 Biotechnology companies, PDS Biotechnology ranks worse than 68.09% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, PDS Biotechnology's Enterprise Value is €8.77 Mil.
PDS Biotechnology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-14.41 Mil. Therefore, PDS Biotechnology's EV-to-OCF for today is -0.61.
The historical rank and industry rank for PDS Biotechnology's EV-to-OCF or its related term are showing as below:
FRA:EU6'
s EV-to-OCF Range Over the Past 10 Years
Min: -0.61 Med: 0 Max: -0.61
Current: -0.61
During the past 13 years, the highest EV-to-OCF of PDS Biotechnology was -0.61. The lowest was -0.61. And the median was .
FRA:EU6's EV-to-OCF is ranked worse than 68.09% of 1407
companies
in the Biotechnology industry
Industry Median: -3.7
vs FRA:EU6: -0.61
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PDS Biotechnology's PE Ratio (TTM) for today is calculated as:
PDS Biotechnology's share price for today is €0.1725.
PDS Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PDS Biotechnology EV-to-OCF Related Terms
PDS Biotechnology EV-to-OCF Historical Data
* Premium members only.
The historical data trend for PDS Biotechnology's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PDS Biotechnology's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PDS Biotechnology EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PDS Biotechnology's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where PDS Biotechnology's EV-to-OCF falls into.
PDS Biotechnology's current Enterprise Value is €8.77 Mil.
PDS Biotechnology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PDS Biotechnology (FRA:EU6) has a EV-to-OCF of -0.61 as of Sep. 02, 2026. According to the industry distribution chart, PDS Biotechnology ranks #958 out of 1407 companies in the Biotechnology industry, placing it in the top 68.1%.
Is PDS Biotechnology's EV-to-OCF too high?
PDS Biotechnology's current EV-to-OCF is -0.61. Based on the distribution chart, PDS Biotechnology ranks #958 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PDS Biotechnology has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's EV-to-OCF compare to KPRX and ASBP?
According to the Biotechnology industry distribution chart, PDS Biotechnology ranks #958 out of 1407 companies for EV-to-OCF. This places PDS Biotechnology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. PDS Biotechnology's current EV-to-OCF is -0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (FRA:EU6) has a current EV-to-OCF of -0.61. The current EV-to-OCF is -0.61. PDS Biotechnology's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For PDS Biotechnology (FRA:EU6), the current EV-to-OCF is -0.61 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
30GF Score
Get the complete analysis for FRA:EU6
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EU6 has been successfully added to your 
